JP2007084564A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007084564A5 JP2007084564A5 JP2006302713A JP2006302713A JP2007084564A5 JP 2007084564 A5 JP2007084564 A5 JP 2007084564A5 JP 2006302713 A JP2006302713 A JP 2006302713A JP 2006302713 A JP2006302713 A JP 2006302713A JP 2007084564 A5 JP2007084564 A5 JP 2007084564A5
- Authority
- JP
- Japan
- Prior art keywords
- alkylene
- pharmaceutical composition
- lower alkyl
- aryl
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000002947 alkylene group Chemical group 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 125000003118 aryl group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000004450 alkenylene group Chemical group 0.000 claims 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims 9
- 125000001188 haloalkyl group Chemical group 0.000 claims 9
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 8
- 239000002246 antineoplastic agent Substances 0.000 claims 7
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 6
- 229930003316 Vitamin D Chemical class 0.000 claims 6
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 229940011871 estrogen Drugs 0.000 claims 6
- 239000000262 estrogen Substances 0.000 claims 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 6
- 235000019166 vitamin D Nutrition 0.000 claims 6
- 239000011710 vitamin D Chemical class 0.000 claims 6
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 6
- 229940046008 vitamin d Drugs 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 claims 5
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims 3
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical class C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims 3
- 206010058019 Cancer Pain Diseases 0.000 claims 3
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical class C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims 3
- 108010069236 Goserelin Chemical class 0.000 claims 3
- 108010000817 Leuprolide Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 229960000997 bicalutamide Drugs 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 claims 3
- 229960000978 cyproterone acetate Drugs 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical class CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims 3
- 229960002074 flutamide Drugs 0.000 claims 3
- 229960002913 goserelin Drugs 0.000 claims 3
- 229960000890 hydrocortisone Drugs 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 229960004125 ketoconazole Drugs 0.000 claims 3
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical class CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims 3
- 229960004338 leuprorelin Drugs 0.000 claims 3
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical class O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 claims 3
- 229960002653 nilutamide Drugs 0.000 claims 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 3
- 229960004618 prednisone Drugs 0.000 claims 3
- 229960003387 progesterone Drugs 0.000 claims 3
- 239000000186 progesterone Substances 0.000 claims 3
- 125000005081 alkoxyalkoxyalkyl group Chemical group 0.000 claims 2
- -1 alkoxyhaloalkyl Chemical group 0.000 claims 2
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 102000017914 EDNRA Human genes 0.000 claims 1
- 101150062404 EDNRA gene Proteins 0.000 claims 1
- 102000002045 Endothelin Human genes 0.000 claims 1
- 108050009340 Endothelin Proteins 0.000 claims 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims 1
- 125000004689 alkyl amino carbonyl alkyl group Chemical group 0.000 claims 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 1
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 claims 1
- 125000005127 aryl alkoxy alkyl group Chemical group 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims 1
- 125000000262 haloalkenyl group Chemical group 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000005020 hydroxyalkenyl group Chemical group 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 0 CCCC*(CCCC)C(C*(C[C@@]([C@@]1O)C2C=C3OCOC3=CC2)[C@]1c1ccc(*)cc1)=O Chemical compound CCCC*(CCCC)C(C*(C[C@@]([C@@]1O)C2C=C3OCOC3=CC2)[C@]1c1ccc(*)cc1)=O 0.000 description 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63338900A | 2000-08-07 | 2000-08-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002517050A Division JP4217068B2 (ja) | 2000-08-07 | 2001-08-06 | エンドセリンアンタゴニストを用いる癌及び癌関連痛の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007084564A JP2007084564A (ja) | 2007-04-05 |
| JP2007084564A5 true JP2007084564A5 (enExample) | 2008-07-31 |
Family
ID=24539436
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002517050A Expired - Fee Related JP4217068B2 (ja) | 2000-08-07 | 2001-08-06 | エンドセリンアンタゴニストを用いる癌及び癌関連痛の治療方法 |
| JP2006302713A Pending JP2007084564A (ja) | 2000-08-07 | 2006-11-08 | エンドセリンアンタゴニストを用いる癌及び癌関連痛の治療方法 |
| JP2006302712A Pending JP2007063288A (ja) | 2000-08-07 | 2006-11-08 | エンドセリンアンタゴニストを用いる癌及び癌関連痛の治療方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002517050A Expired - Fee Related JP4217068B2 (ja) | 2000-08-07 | 2001-08-06 | エンドセリンアンタゴニストを用いる癌及び癌関連痛の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006302712A Pending JP2007063288A (ja) | 2000-08-07 | 2006-11-08 | エンドセリンアンタゴニストを用いる癌及び癌関連痛の治療方法 |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1347751B1 (enExample) |
| JP (3) | JP4217068B2 (enExample) |
| KR (1) | KR20030027007A (enExample) |
| CN (1) | CN1635878A (enExample) |
| AR (1) | AR031122A1 (enExample) |
| AT (1) | ATE465728T1 (enExample) |
| AU (2) | AU2001281134B2 (enExample) |
| BG (1) | BG107577A (enExample) |
| BR (1) | BR0108865A (enExample) |
| CA (1) | CA2416879C (enExample) |
| DE (1) | DE60141979D1 (enExample) |
| HU (1) | HUP0302977A2 (enExample) |
| IL (1) | IL153769A0 (enExample) |
| MX (1) | MXPA03000984A (enExample) |
| NO (1) | NO20030593D0 (enExample) |
| NZ (1) | NZ523562A (enExample) |
| PE (1) | PE20020273A1 (enExample) |
| PL (1) | PL366160A1 (enExample) |
| SK (1) | SK1782003A3 (enExample) |
| TW (1) | TWI306760B (enExample) |
| WO (1) | WO2002011713A2 (enExample) |
| ZA (1) | ZA200300253B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0219660D0 (en) * | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
| GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
| PL1765391T3 (pl) * | 2004-06-07 | 2013-08-30 | Qu Biologics Inc | Kompozycje bakteryjne do leczenia nowotworów |
| US9107864B2 (en) | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| CA2904447C (en) | 2007-08-22 | 2017-01-03 | Abbvie Deutschland Gmbh & Co Kg | Therapy for complications of diabetes |
| WO2011114103A1 (en) | 2010-03-18 | 2011-09-22 | Biolipox Ab | Pyrimidinones for use as medicaments |
| ES2645509T3 (es) | 2010-07-26 | 2017-12-05 | Qu Biologics Inc | Composiciones antiinflamatorias inmunogénicas |
| CN102485238A (zh) * | 2010-12-06 | 2012-06-06 | 陈炯华 | 芎芷镇痛方 |
| CA3254723A1 (en) | 2014-05-02 | 2025-04-15 | Qu Biologics Inc | ANTIMICROBIAL IMMUNOMODULATION |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6063911A (en) * | 1993-12-01 | 2000-05-16 | Marine Polymer Technologies, Inc. | Methods and compositions for treatment of cell proliferative disorders |
| NZ330818A (en) * | 1996-02-13 | 2000-05-26 | Abbott Lab | Benzo-1, 3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists |
| TR200101234T2 (tr) | 1997-08-04 | 2002-06-21 | Abbott Laboratories | Endotelin antagonistleri. |
| AU4382499A (en) * | 1998-12-11 | 2000-07-03 | Mactapes Limited | Curtain heading tape manufacture |
| US6545048B1 (en) * | 1999-06-29 | 2003-04-08 | California Institute Of Technology | Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity |
-
2001
- 2001-07-24 TW TW090118053A patent/TWI306760B/zh active
- 2001-08-06 CA CA002416879A patent/CA2416879C/en not_active Expired - Fee Related
- 2001-08-06 WO PCT/US2001/024716 patent/WO2002011713A2/en not_active Ceased
- 2001-08-06 IL IL15376901A patent/IL153769A0/xx unknown
- 2001-08-06 SK SK178-2003A patent/SK1782003A3/sk unknown
- 2001-08-06 AT AT01959595T patent/ATE465728T1/de not_active IP Right Cessation
- 2001-08-06 CN CNA018169929A patent/CN1635878A/zh active Pending
- 2001-08-06 AR ARP010103755A patent/AR031122A1/es not_active Application Discontinuation
- 2001-08-06 AU AU2001281134A patent/AU2001281134B2/en not_active Ceased
- 2001-08-06 AU AU8113401A patent/AU8113401A/xx active Pending
- 2001-08-06 DE DE60141979T patent/DE60141979D1/de not_active Expired - Lifetime
- 2001-08-06 EP EP01959595A patent/EP1347751B1/en not_active Expired - Lifetime
- 2001-08-06 PE PE2001000782A patent/PE20020273A1/es not_active Application Discontinuation
- 2001-08-06 PL PL01366160A patent/PL366160A1/xx unknown
- 2001-08-06 HU HU0302977A patent/HUP0302977A2/hu unknown
- 2001-08-06 JP JP2002517050A patent/JP4217068B2/ja not_active Expired - Fee Related
- 2001-08-06 BR BR0108865-3A patent/BR0108865A/pt not_active Application Discontinuation
- 2001-08-06 NZ NZ523562A patent/NZ523562A/en unknown
- 2001-08-06 KR KR10-2003-7001735A patent/KR20030027007A/ko not_active Ceased
- 2001-08-06 MX MXPA03000984A patent/MXPA03000984A/es active IP Right Grant
-
2003
- 2003-01-09 ZA ZA200300253A patent/ZA200300253B/en unknown
- 2003-02-06 NO NO20030593A patent/NO20030593D0/no not_active Application Discontinuation
- 2003-02-21 BG BG107577A patent/BG107577A/bg unknown
-
2006
- 2006-11-08 JP JP2006302713A patent/JP2007084564A/ja active Pending
- 2006-11-08 JP JP2006302712A patent/JP2007063288A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9295679B2 (en) | Prodrugs of C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity | |
| US12128048B2 (en) | Combination therapies using PRMT5 inhibitors for the treatment of cancer | |
| KR101004224B1 (ko) | 인 함유 화합물 및 이의 용도 | |
| ES2916721T3 (es) | Terapia de combinación que incluye un inhibidor de MDM2 y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
| ES2552087T3 (es) | Nuevos profármacos de inhibidores de CYP17 esteroidales/antiandrógenos | |
| US11891404B2 (en) | Substituted macrocyclic indole derivatives | |
| US12171765B2 (en) | Combination therapies using PRMT5 inhibitors for the treatment of cancer | |
| JP2007084564A5 (enExample) | ||
| JP2005533807A5 (enExample) | ||
| JP2007520452A5 (enExample) | ||
| HUE026645T2 (en) | Estrra-1,3,5 (10), 16-tetraene-3-carboxamide derivatives, a process for their preparation, pharmaceutical compositions containing them, and their use in the manufacture of a medicament. | |
| CN114702503B (zh) | 甲酮化合物 | |
| JP2007063288A5 (enExample) | ||
| ES2300877T3 (es) | Derivados de esteroides glucosilados con actividad antimigratoria. | |
| ES2992773T3 (en) | Use of thyroid beta-agonists | |
| EP4412607A1 (en) | Combination therapies using prmt5 inhibitors for the treatment of cancer | |
| RU2005128831A (ru) | Обладающие противоопухолевым действием 2-замещенные эстра-1,3,5( 10 )-триен-3-илсульфаматы | |
| WO2016102775A1 (en) | PRODRUGS OF 17β-HSD1 -INHIBITORS | |
| US20140186266A1 (en) | Conjugates of nitroimidazoles and their use as chemotherapeutic agents | |
| CA3131706A1 (en) | Compounds for targeted therapies of castration resistant prostate cancer | |
| TW201825478A (zh) | ［４－（苯基磺醯基）哌嗪－１－-基］（１ｈ－１，２，３－三唑－４-基）甲酮 | |
| WO2025217015A1 (en) | Combination therapies using prmt5 inhibitors and kras g12d inhibitors for the treatment of cancer | |
| ES2265583T3 (es) | 2"-oxo-voruscharina y derivados de la misma. | |
| WO2025217007A1 (en) | Combination therapies using prmt5 inhibitors and immune checkpoint inhibitors for the treatment of cancer | |
| CN100448880C (zh) | 2"氧代-voruscharin及其衍生物 |